Novo Nordisk Halts Two Heart-Failure Studies Due to Lack of Efficacy
By Adria Calatayud
Novo Nordisk said it is ending two heart-failure studies early after concluding it was unlikely they would achieve the expected outcome.
The two trials evaluated Novo Nordisk's experimental cardiovascular drug ziltivekimab to see whether it could be used to treat patients with heart failure and inflammation. The decision comes after the drugmaker said in late July that the medicine didn't reduce risk of heart attack or stroke in a different study.
The decision to stop the trials early was based on a recommendation from the data-monitoring committee, a spokeswoman for the Danish pharmaceutical company said. There was a low likelihood that the studies would lead to a different outcome from the prior study that failed, she added.
Endpoints News first reported the news.
A fourth study that looks at ziltivekimab in an acute setting following a heart attack will continue as planned, with data due in the first half of next year, Novo Nordisk said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
September 07, 2026 06:56 ET (10:56 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States